Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In addition to taking either semaglutide or placebo for the trial, all participants also received standard-of-care treatment for cardiovascular disease, such as cholesterol-modifying medications, antiplatelet therapies, beta blockers or other treatments
To view or add a comment, sign in Eli Lilly (LLY) announced recent results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels
This extended gastric retention leads to prolonged satiety after meals and a more gradual release of nutrients into the bloodstream, helping reduce sharp post-meal glucose fluctuations
The glucagon receptor is the differentiator
US$ 27.34
US$ 29.84
US$ 20.64
US$ 22.32
US$ 21.86
US$ 21.38
US$ 21.76
US$ 22.17
US$ 22.57
